Yufei Liu, M.D., Ph.D.

800-826-4673
Yufei Liu, M.D., Ph.D.
Radiation Oncologist
Clinical Expertise
  • Lung Cancer
  • Gastrointestinal Cancers
  • Colorectal Cancer
  • Esophageal Cancer
  • Pancreas Cancer
  • Hepatobiliary Malignancies
  • Stereotactic Body Radiation Therapy (SBRT)/Stereotactic Ablative Radiation Therapy (SABR)
  • Stereotactic Radiosurgery
Other Languages Spoken
Mandarin
Academic Appointments
  • Assistant Clinical Professor, Department of Radiation Oncology
Clinical Teams
Radiation Oncology

Radiation oncologist Yufei Liu, M.D., Ph.D., was called to be a physician out of his desire to alleviate patients’ suffering during their most vulnerable times and to translate the latest scientific discoveries into better cancer treatments. He understands that every patient is unique and works with them to develop personalized treatment plans that meet their needs and goals.

Dr. Liu has specialized expertise in delivering precisely targeted conformal radiation with intensity-modulated radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery. He utilizes advanced imaging and biomarker guidance to maximize tumor control and minimize side effects.

A physician-scientist, he leads studies advancing precision medicine to maximize the effectiveness of treatments based on understanding tumors at the molecular level. He has particular interests in reducing the side effects of radiation and improving the synergy of radiation with immunotherapy. When he joined City of Hope in 2023, Dr. Liu had over 20 peer-reviewed scientific publications in journals such as Science, Nature Cancer, and JAMA Network Open. His research has been recognized with the Jeffrey Lee Cousins Fellowship in Lung Cancer Research during his residency at MD Anderson and with awards for research excellence at annual meetings of the American Society for Radiation Oncology.  

Outside the hospital, he enjoys hiking and exploring California's beautiful landscape, as well as reading, traveling, playing the piano, and stargazing.

Location

Education & Experience

Degrees

  • 2018, Doctor of Medicine, Stanford University School of Medicine, Stanford, California
  • 2014, Doctor of Philosophy, Molecular & Cell Biology, University of California, Berkeley, California
  • 2008, Bachelor of Ards, Molecular Biology, Princeton University, Princeton, New Jersey

Residency

  • 2023, Residency, Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas

Internship

  • 2019, Internship, Internal Medicine, University of Texas Health Science Center, Houston, Texas

Professional Experience

  • 2023-present, Assistant Clinical Professor, Department of Radiation Oncology, City of Hope, Duarte, California

Publications

  • Liu Y, Zhang Z, Rinsurongwakong W, Gay CM, Le X., Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, and Lin SH. Association of Driver Oncogene Variations with Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation and Consolidative Durvalumab. 2022. JAMA Netw. Open 5, e2215589.
  • Niedzielski J, Liu Y, Martin R, Perles L, Beddar S, Rebueno N, Koay E, Taniguchi C, Holliday E, Das P, Smith G, Minsky B, Ludmir E, Koong A, and Sawakuchi G. Dosimetric effects of interfractional changes in GI anatomy for pancreatic SBRT patients utilizing daily CT-on-Rails imaging: Are we flying blind with CBCT image guidance? 2021. IJROBP 111, 1298-1309.
  • Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen A, O’Reilly M, Liao Z, Chang J, Lee P, Lin SH. Prognosis of Severe Lymphopenia after Postoperative Radiotherapy in Non-small Cell Lung Cancer: Results of a Long-Term Follow Up Study. 2021. Clin. Transl. Rad. Oncol. 28, 54-61.
  • Binkley M, Koenig J, Xiang M, Liu Y, Sodji Q, Maxim P, Diehn M, and Loo B. Predicting per-lesion local recurrence in locally advanced lung cancer using pre- and mid-treatment metabolic tumor volume. 2020. Rad. Oncol. 15, 114.
  • Moding E, Liu Y, Nabet B, Chabon J, Chaudhuri A, Hui A, Bonilla R, Ko R, Yoo C, Gojenola L, Jones C, He J, Qiao Y, Xu T, Heymach J, Tsao A, Liao Z, Gomez D, Das M, Padda S, Ramchandran K, Neal J, Wakelee H, Loo B, Lin SH, Alizadeh A, and Diehn M. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. 2020. Nature Cancer 1, 176-183.
  • Grade M, Koenig J, Qian Y, Sandhu N, Liu Y, Turner B, von Eyben R, Knox S, and Dudley S. Outcomes and characteristics of patients treated with emergent palliative radiotherapy. 2019. Pract. Rad. Oncol. 9, e203-e209.
  • Qian Y, von Eyben R, Liu Y, Chin FT, Miao Z, Apte S, Carter JN, Binkley MS, Pollom EL, Harris JP, Prionas ND, Kissel M, Simmons A, Diehn M, Schultz DB, Brown JM, Maxim PG, Koong AC, Graves EE, Loo BW. 18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated with Highly Conformal Radiation Therapy. 2018. Int J Radiat Oncol Biol Phys. 102, 1183-1192.
  • Mohrin M*, Widjaja A*, Liu Y, Luo H, and Chen D. The mitochondrial unfolded protein response is activated upon hematopoietic stem cell exit from quiescence. 2018. Aging Cell 17, e12756.
  • Rao AD*, Liu Y*, von Eyben R, Hsu CH, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, and Herman JM. Multiplex proximity ligation assay to identify potential prognostic biomarkers for improved survival in locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy. 2018. Int J Radiat Oncol Biol Phys. 100, 486-489.
  • Liu Y, von Eyben R, and Kidd E. Consideration of Patient and Disease Characteristics in Selecting Radiation Regimens for Treatment of Bone Metastases. 2017. Pract. Rad. Oncol. 7, 403-410.

View more publications